The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.
Last year's increase in CME support from manufacturers came after six straight years of declining budgets.
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.